In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aqualis ASA

aqualis.no

Latest From Aqualis ASA

Scrip 100: Chugai USA's new CMO is a Man for All Regions

When the Swiss-born and transatlantic-bred Dr Athos Gianella-Borradori took up his new role as Chugai Pharma USA's chief medical officer in April, an international perspective was vital. So he took for his inspiration Carlos Goshn, the French-Lebanese-Brazilian businessman famous for turning round the Japanese car maker Nissan. As one of the first non-Japanese CEOs of a very traditional Japanese company, Goshn was the perfect role model in a job that would demand high levels of cultural awareness.

Cancer Switzerland

ReNeuron names Olav Hellebø CEO

UK stem cell therapy company ReNeuron has appointed Olav Hellebø CEO with immediate effect. Mr Hellebø most recently served as CEO of Clavis Pharma. Prior to that, he headed up the global biologics franchise at UCB Pharma. Michael Hunt, ReNeuron's CEO since 2005, will remain on the board as CFO.

As Algeta's sibling, can Nordic Nanovector find the same success?

Privately held cancer drug developer Nordic Nanovector – a spin-out company from the same founders who built Xofigo creator Algeta – is raising NOK150m ($25m) through a private placement of shares in order to progress development of its early-stage-blood cancer radio-immunotherapy, Betalutin. The CEO told Scrip that if all goes well, the company hopes to find a strategic partner and launch an IPO next year. However, there is a lot still to prove.

Cancer Norway

Chugai appoints new US CMO

Chugai Pharma USA (CPUSA) a wholly owned subsidiary of Chugai Pharmaceutical, a Tokyo, Japan-based member of the Roche Group, has named Dr Athos Gianella-Borradori chief medical officer, CPUSA. Dr Gianella-Borradori has more than 20 years' experience in international drug research. His prior roles include senior positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland) and Clavis Pharma (Norway). 

United Kingdom Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Clavis Pharma ASA
  • ConPharma AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Aqualis ASA
  • Senior Management
  • Gunnar Manum, Acting CEO
    Christian Opsahl , CFO
    Ole Henrik Eriksen, COO
  • Contact Info
  • Aqualis ASA
    Phone: (47) 23 01 49 90
    Sjølyst Plass 2, 3.etg.
    Oslo, NO-0278
    Norway
Advertisement
Advertisement
UsernamePublicRestriction

Register